Document Detail


Use of terbinafine in rare and refractory mycoses.
MedLine Citation:
PMID:  18230029     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Terbinafine is the only systemic allylamine antifungal currently available. Its mechanism of action is unique and sets it apart from other agents. Although it is primarily used for dermatophyte infections, such as onychomycosis and tinea pedis, terbinafine has broad in vitro activity against a variety of non-dermatophyte fungal pathogens, including Candida spp. and many molds. In addition, synergistic activity is noted with other antifungals, notably triazoles. Multiple case reports exist of its use for unusual and refractory fungal infections, but no systematic review is available. We review the current literature with regard to in vitro data and clinical experience with terbinafine in the treatment of rare and refractory mycoses.
Authors:
Sanjay G Revankar; Michael D Nailor; Jack D Sobel
Related Documents :
18423289 - Evidence-based oral and maxillofacial surgery.
19459889 - On advocacy by environmental scientists: what, whether, why, and how.
20608269 - Methodology for the systematic reviews of occupational therapy for children and adolesc...
18034239 - Inter-observer reproducibility in reporting on renal drainage in children with hydronep...
19302699 - Calculation of nnts in rcts with time-to-event outcomes: a literature review.
15030779 - Using sonochemistry for the fabrication of nanomaterials.
22964289 - Etiologic and epidemiologic analysis of hand, foot, and mouth disease in guangzhou city...
15772549 - Solitary cysticercosis in the intermuscular area of the thigh: a rare and unusual pseud...
16006489 - Lingual nerve injury associated with the proseal laryngeal mask airway: a case report a...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Future microbiology     Volume:  3     ISSN:  1746-0921     ISO Abbreviation:  -     Publication Date:  2008 Feb 
Date Detail:
Created Date:  2008-01-30     Completed Date:  2008-02-14     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101278120     Medline TA:  Future Microbiol     Country:  England    
Other Details:
Languages:  eng     Pagination:  9-17     Citation Subset:  IM    
Affiliation:
Wayne State University, Division of Infectious Diseases, Harper University Hospital, 3990 John R. St., 5 Hudson Detroit, MI 48201, USA. srevankar@med.wayne.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antifungal Agents / pharmacokinetics,  therapeutic use*
Candida / drug effects
Dermatomycoses / drug therapy
Drug Resistance, Fungal
Humans
Mycoses / drug therapy*,  microbiology
Naphthalenes / pharmacokinetics,  therapeutic use*
Treatment Outcome
Triazoles / pharmacokinetics,  therapeutic use
Chemical
Reg. No./Substance:
0/Antifungal Agents; 0/Naphthalenes; 0/Triazoles; 91161-71-6/terbinafine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Expression and regulation of major histocompatibility complex on neural stem cells and their lineage...
Next Document:  Do Aspergillus species produce biofilm?